E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence

Journal of Virology

Volumn 82, Issue 12, 2008, Pages 6024-6033

  Lee, Eva ^a   Lobigs, Mario ^a  

^a Biology and Environment   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ENVELOPE PROTEIN; GLYCOSAMINOGLYCAN; YELLOW FEVER VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD FLOW; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SAFETY; GENETIC STABILITY; IN VIVO STUDY; MOUSE; MUTATION; NEUROTROPISM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRUS INFECTION; VIRUS VIRULENCE; WILD TYPE; YELLOW FEVER FLAVIVIRUS;

AEDES; ANIMALS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CRICETINAE; GLYCOSAMINOGLYCANS; MICE; MICE, KNOCKOUT; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRULENCE; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

MUS; YELLOW FEVER VIRUS;

EID: 44949131854     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02509-07     Document Type: Article

References (40)

1. Barba-Spaeth, G., R. S. Longman, M. L. Albert, and C. M. Rice. 2005. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J. Exp. Med. 202:1179-1184.
2. Barrett, A. D., and E. A. Gould. 1986. Comparison of neurovirulence of different strains of yellow fever virus in mice. J. Gen. Virol. 67:631-637.
3. Bernard, K. A., W. B. Klimstra, and R. E. Johnston. 2000. Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology 276:93-103.
4. Bredenbeek, P. J., E. A. Kooi, B. Lindenbach, N. Huijkman, C. M. Rice, and W. J. Spaan. 2003. A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication. J. Gen. Virol. 84:1261-1268.
5. Byrnes, A. P., and D. E. Griffin. 2000. Large-plaque mutants of Sindbis virus show reduced binding to heparan sulfate, heightened viremia, and slower clearance from the circulation. J. Virol. 74:644-651.
6. Chambers, T. J., and M. Nickells. 2001. Neuroadapted yellow fever virus 17D: genetic and biological characterization of a highly mouse-neurovirulent virus and its infectious molecular clone. J. Virol. 75:10912-10922.
7. Chen, Y., T. Maguire, R. E. Hileman, J. R. Fromm, J. D. Esko, R. J. Linhardt, and R. M. Marks. 1997. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3:866-871.
8. dos Santos, C. N., P. R. Post, R. Carvalho, I. I. Ferreira, C. M. Rice, and R. Galler. 1995. Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus Res. 35:35-41.
9. Germi, R., J. M. Crance, D. Garin, J. Guimet, H. Lortat-Jacob, R. W. Ruigrok, J. P. Zarski, and E. Drouet. 2002. Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus. Virology 292: 162-168.
10. Hahn, C. S., J. M. Dalrymple, J. H. Strauss, and C. M. Rice. 1987. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc. Natl. Acad. Sci. USA 84:2019-2023.
11. Klimstra, W. B., K. D. Ryman, and R. E. Johnston. 1998. Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor. J. Virol. 72:7357-7366.
12. Kuhn, R. J., W. Zhang, M. G. Rossmann, S. V. Pletnev, J. Corver, E. Lenches, C. T. Jones, S. Mukhopadhyay, P. R. Chipman, E. G. Strauss, T. S. Baker, and J. H. Strauss. 2002. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108:717-725.
13. Lai, C. J., and T. P. Monath. 2003. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. Adv. Virus Res. 61:469-509.
14. Lee, E., R. A. Hall, and M. Lobigs. 2004. Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses. J. Virol. 78:8271-8280.
15. Lee, E., and M. Lobigs. 2002. Mechanism of virulence attenuation of glycosaminoglycan-binding variants of Japanese encephalitis virus and Murray Valley encephalitis virus. J. Virol. 76:4901-4911.
16. Lee, E., and M. Lobigs. 2000. Substitutions at the putative receptor-binding site of an encephalitic flavivirus alter virulence and host cell tropism and reveal a role for glycosaminoglycans in entry. J. Virol. 74:8867-8875.
17. Lee, E., M. Pavy, N. Young, C. Freeman, and M. Lobigs. 2006. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. Antivir. Res. 69:31-38.
18. Lee, E., P. J. Wright, A. Davidson, and M. Lobigs. 2006. Virulence attenuation of Dengue virus due to augmented glycosaminoglycan-binding affinity and restriction in extraneural dissemination. J. Gen. Virol. 87:2791-2801.
19. Lefeuvre, A., H. Contamin, T. Decelle, C. Fournier, J. Lang, V. Deubel, and P. Marianneau. 2006. Host-cell interaction of attenuated and wild-type strains of yellow fever virus can be differentiated at early stages of hepatocyte infection. Microbes Infect. 8:1530-1538.
20. Licon Luna, R. M., E. Lee, A. Mullbacher, R. V. Blanden, R. Langman, and M. Lobigs. 2002. Lack of both Fas ligand and perforin protects from flavivirus-mediated encephalitis in mice. J. Virol. 76:3202-3211.
21. Lobigs, M., R. Usha, A. Nestorowicz, I. D. Marshall, R. C. Weir, and L. Dalgarno. 1990. Host cell selection of Murray Valley encephalitis virus variants altered at an RDG sequence in the envelope protein and in mouse virulence. Virology 176:587-595.
22. MacDonald, G. H., and R. E. Johnston. 2000. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J. Virol. 74:914-922.
23. Mandl, C. W., H. Kroschewski, S. L. Allison, R. Kofler, H. Holzmann, T. Meixner, and F. X. Heinz. 2001. Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo. J. Virol. 75:5627-5637.
24. McArthur, M. A., M. T. Suderman, J. P. Mutebi, S. Y. Xiao, and A. D. Barrett. 2003. Molecular characterization of a hamster viscerotropic strain of yellow fever virus. J. Virol. 77:1462-1468.
25. McElroy, K. L., K. A. Tsetsarkin, D. L. Vanlandingham, and S. Higgs. 2005. Characterization of an infectious clone of the wild-type yellow fever virus Asibi strain that is able to infect and disseminate in mosquitoes. J. Gen. Virol. 86:1747-1751.
26. Modis, Y., S. Ogata, D. Clements, and S. C. Harrison. 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. USA 100:6986-6991.
27. Monath, T. P. 2005. Yellow fever vaccine. Expert Rev. Vaccines 4:553-574.
28. Monath, T. P., and A. D. Barrett. 2003. Pathogenesis and pathophysiology of yellow fever. Adv. Virus Res. 60:343-395.
29. Nickells, M., and T. J. Chambers. 2003. Neuroadapted yellow fever virus 17D: determinants in the envelope protein govern neuroinvasiveness for SCID mice. J. Virol. 77:12232-12242.
30. Raman, R., V. Sasisekharan, and R. Sasisekharan. 2005. Structural insights into biological roles of protein-glycosaminoglycan interactions. Chem. Biol. 12:267-277.
31. Rey, F. A, F. X. Heinz, C. Mandl, C. Kunz, and S. C. Harrison. 1995. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375:291-298.
32. Rice, C. M., A. Grakoui, R. Galler, and T. J. Chambers. 1989. Transcription of infectious yellow fever virus RNA from full-length cDNA templates produced by in vitro ligation. New Biol. 1:285-296.
33. Rice, C. M., E. M. Lenches, S. R. Eddy, S. J. Shin, R. L. Sheets, and J. H. Strauss. 1985. Nucleotide sequence of yellow fever virus: Implications for flavivirus gene expression and evolution. Science 229:726-733.
34. Ryman, K. D., T. N. Ledger, G. A. Campbell, S. J. Watowich, and A. D. Barrett. 1998. Mutation in a 17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice. Virology 244:59-65.
35. Ryman, K. D., H. Xie, T. N. Ledger, G. A. Campbell, and A. D. Barrett. 1997. Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. Virology 230:376-380.
36. Sa-Carvalho, D., E. Rieder, B. Baxt, R. Rodarte, A. Tanuri, and P. W. Mason. 1997. Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J. Virol. 71:5115-5123.
37. Schlesinger, J. J., S. Chapman, A. Nestorowicz, C. M. Rice, T. E. Ginocchio, and T. J. Chambers. 1996. Replication of yellow fever virus in the mouse central nervous system: comparison of neuroadapted and non-neuroadapted virus and partial sequence analysis of the neuroadapted strain. J. Gen. Virol. 77:1277-1285.
38. Tesh, R. B., H. Guzman, A. P. da Rosa, P. F. Vasconcelos, L. B. Dias, J. E. Bunnell, H. Zhang, and S. Y. Xiao. 2001. Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J. Infect. Dis. 183:1431-1436.
39. Theiler, M., and H. H. Smith. 2000. The use of yellow fever virus modified by in vitro cultivation for human immunization (J. Exp. Med. 65:787-800, 1937.) Rev. Med. Virol. 10:6-16.
40. van den Broek, M. F., U. Muller, S. Huang, M. Aguet, and R. M. Zinkernagel. 1995. Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J. Virol. 69:4792-4796.